Drugs / Allogeneic adipose-derived mesenchymal stem cells (MSC)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05362786 | Jul 2022 → Jul 2024 | chronic kidney disease | LaTonya J. Hickson | Completed | No outcome recorded |
| Phase 1 | NCT04869761 | Oct 2021 → Apr 2023 | diabetic kidney disease, type 1 diabetes mellitus, type 2 diabetes mellitus | LaTonya J. Hickson | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic adipose-derived mesenchymal stem cells (MSC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04869761 ↗ |
| Known as | MSC | “Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion” NCT04869761 ↗1“Allogeneic adipose-derived mesenchymal stem cells (MSC)” NCT05362786 ↗ |
| Modality | Cell therapy | “allogeneic mesenchymal stem / stromal cell therapy” NCT04869761 ↗ |
| Route | Intravenous | “intravenous delivery” NCT04869761 ↗ |